Basic Course In Biomedical Research: What It Is And Why It Matters
However, to receive the course completion e-Certificate, participants must appear for an online, offsite, proctored examination. The Indian Council of Medical Research will notify examination details on its official website (nie.gov.in/icmr_sph/BCBR), which also hosts information on the course schedule, content, registration, and qualifying criteria. Notably, only the official online e-Certificate will be recognised as valid proof of course completion.
With the growing importance of evidence-based medicine, the BCBR course has become integral to medical education and faculty development. Understanding research methods is crucial for interpreting biomedical literature effectively, and this course helps bridge that gap for both learners and educators in the field.
For postgraduate medical students, completing the BCBR course is now mandatory. As per amendments notified on December 11, 2019, by the Board of Governors in supersession of the Medical Council of India, all postgraduate students must complete the course by the end of their second semester.
For medical teachers, the course is equally essential. Faculty members are expected not only to train and mentor students but also to conduct and publish research. Recognising this, regulatory changes introduced on February 12, 2020, made it compulsory for medical teachers to complete the BCBR course for promotions to various teaching posts.
Through the BCBR course, ICMR-NIE seeks to strengthen the foundation of medical research in India, ensuring both students and teachers are well-equipped with the knowledge.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 days ago
- Time of India
New app by AIIMS, Nagpur, set to transform lives of children with epilepsy
Nagpur: In a major step toward creating safer and more inclusive schools for children with epilepsy, AIIMS, Nagpur, has launched a first-of-its-kind mobile application — Tele-ESSI — that helps teachers and parents identify and manage seizures through simple, animated learning tools. The app is already making a difference by creating awareness among teachers who were earlier unsure or fearful of what to do when a child has a seizure. With this easy-to-use tool, teachers are being trained to respond calmly instead of panicking, which could bring a major shift in how children with epilepsy are supported in schools. "We want every teacher to be prepared to handle the situation. Through this app, we are spreading knowledge that will empower schools, reduce fear, and change the lives of children living with epilepsy," said Dr Prashant Joshi, executive director of AIIMS, Nagpur, while launching the app. The app is part of a national project called Tele-ESSI (Tele-school Health-led Epilepsy Smart Schools in India), led by AIIMS, Nagpur, in collaboration with the Indian Council of Medical Research (ICMR). The goal is to equip at least one staff member in every school with practical skills to manage seizure situations confidently. The app is available in regional languages so that it can be used even in rural and remote areas by teachers, parents, school staff, and primary healthcare workers. "This app simplifies medical knowledge through everyday language. It breaks the fear barrier and gives confidence to teachers and parents to act in time, without panic," said Dr Shikha Jain, paediatric neurologist and principal investigator of the project. "We hope this will reduce the number of missed school days, help avoid injuries during seizures, and stop the social stigma children with epilepsy often face," she added. Epilepsy affects nearly 5 million children in India, but many go undiagnosed or untreated. Schools are where children spend most of their time, but teachers often lack the training to deal with seizures, leading to fear, confusion, and misinformation. With the Tele-ESSI app, AIIMS, Nagpur, wants to ensure that no child is left behind due to fear or lack of awareness. Teachers using the app are already learning how to give seizure first aid, something that can save lives and bring peace of mind to parents. The initiative is backed by a dedicated team including Dr Sujiv Akkilagunta, Dr Urmila Dahake, and Dr Prasenjit Patil, who helped organise the launch and training programmes. BOX HELPING HAND The Tele-ESSI app uses cartoon-style animated videos to answer three simple but critical questions: How to identify a seizure? What to do immediately when a child has a seizure? When should the child be taken to a hospital?
News18
2 days ago
- News18
How Much Should You Weigh For Your Height? Here's What Experts Say
Last Updated: If a man's waist circumference exceeds 90 cm, or a woman's is more than 80 cm, it may indicate a high risk of obesity-related complications, even if their BMI appears normal Maintaining a healthy balance between height and weight is not just about appearance, it's a key indicator of overall health. Medical science has long relied on a standard method to assess this balance: the Body Mass Index, or BMI. However, experts say that while BMI offers a helpful guideline, it doesn't paint the full picture, especially for South Asian body types. 'Body balance is essential for any person to be healthy. If the right ratio increases, everything is fine. If the wrong ratio increases, then it is a call for disease," said experts. As people grow, their height and weight tend to increase until a point when height plateaus. If the body continues gaining weight disproportionately, or loses it drastically, it could signal an underlying health imbalance. Understanding BMI BMI = Weight (kg) / Height² (meters) A BMI between 18.5 and 24.9 is considered healthy. A score below 18.5 signals underweight, while a BMI above 25 may suggest overweight or obesity. But here's where the Indian perspective complicates things. BMI Doesn't Tell The Whole Story While BMI is a helpful starting point, it's not always accurate, especially for Indians. 'BMI does not measure belly fat, on the other hand belly fat is the most dangerous type of obesity," experts caution. Recognising this, the Indian Council of Medical Research (ICMR) has recommended going a step further, measuring abdominal fat. If a man's waist circumference exceeds 90 cm, or a woman's is more than 80 cm, it may indicate a high risk of obesity-related complications, even if their BMI appears normal. What Should You Weigh? A Height-Wise Reference Below is a weight range chart to help assess what your approximate weight should be for your height. The left column shows height, while the next two columns indicate ideal weight ranges for women and men, respectively. 137 cm / 4'6" 28.5 – 34.9 28.5 – 34.9 147 cm / 4′10" 36.4 – 44.9 38.5 – 46.7 152 cm / 5′0" 40.8 – 49.9 43.1 – 53.0 160 cm / 5′3" 47.2 – 57.6 50.8 – 61.6 165 cm / 5′5" 51.2 – 62.6 55.3 – 68.0 168 cm / 5′6" 53.0 – 64.8 58.0 – 70.7 170 cm / 5′7" 55.3 – 67.6 60.3 – 73.9 173 cm / 5′8" 57.1 – 69.8 63.0 – 76.6 175 cm / 5′9" 59.4 – 72.6 65.3 – 79.8 178 cm / 5′10" 61.2 – 74.8 67.6 – 83.0 180 cm / 5′11" 63.5 – 77.5 70.3 – 85.7 183 cm / 6′0" 65.3 – 79.8 72.6 – 88.9 188 cm / 6′2" 69.4 – 84.8 77.5 – 94.8 193 cm / 6′4" 73.5 – 89.8 82.5 – 100.6 195 cm / 6′5" 75.7 – 92.5 84.8 – 103.8 These numbers provide general guidance. The ideal weight can also vary based on muscle mass, bone density, lifestyle, and underlying health conditions. First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hindustan Times
4 days ago
- Hindustan Times
ICMR's anti-malaria vaccine still 6-7 years away
The Indian Council of Medical Research (ICMR) has invited an expression of interest for technology transfer to commercialise its anti-malaria vaccine candidate that it is developing in partnership with the department of biotechnology, even though the vaccine is likely to take at least six to seven years to be ready for use, according to people familiar with the matter. Malaria continues to pose serious challenges to public health and economies, particularly in the tropical and subtropical regions around the world. (Unsplash) According to the projected timeline, accessed by HT, the 'Good Manufacturing Practice (GMP) production and toxicology studies' will take approximately two years; 'phase 1 clinical trial, including regulatory approval', will take another two years; 'Phase 2b and Phase 3 clinical trials' will take approximately two and a half years; and post-trial regulatory clearance and licensing for marketing would take approximately six months. (Each stage includes a buffer period of ± six months.) The recombinant chimeric multi-stage malaria vaccine (AdFalciVax) is being indigenously developed against plasmodium falciparum— the parasite that predominantly causes severe and fatal malaria, according to ICMR. 'In early stages, the vaccine candidate looks useful in preventing plasmodium falciparum infection in humans and minimising its community transmission,' it added. Malaria continues to pose serious challenges to public health and economies, particularly in the tropical and subtropical regions around the world. According to data shared by the government, globally in 2023, there were almost 263 million estimated malaria cases in 83 malaria-endemic countries, an increase of 11 million cases compared with 2022. India accounted for half of all estimated malaria cases in the South-East Asia region in 2023. ICMR has invited applications from organisations, companies, and manufacturers from across the country. 'ICMR-Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB)— one of the constituent institutes of ICMR has led development of a technology entitled 'A recombinant chimeric multi-stage malaria vaccine (AdFalciVax) against Plasmodium falciparum'… and ICMR-RMRCBB has technical know-how of process to produce this technology. The pre-clinical validation of this technology has been conducted in collaboration with ICMR-National Institute of Malaria Research (ICMR-NIMR), another constituent institutes of ICMR, and National Institute of Immunology (NII), New Delhi, an autonomous research institute of the Department of Biotechnology, Government of India,' the ICMR invite said. AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of plasmodium falciparum. Country's biomedical research regulator, however, emphasised that the vaccine candidate is in its early research and development phases and is not yet available for any clinical use or commercialisation. The vaccine has shown excellent efficacy in the preclinical stage of development, ICMR said in a statement. 'Preclinical data suggest that AdFalciVax may have advantages over existing single-stage vaccines (such as RTS,S/AS01 and R21/Matrix-M), including: Broader protection by targeting two vulnerable parasite stages; lower risk of immune evasion and potential for better long-term immunity; extended thermal stability with functionality maintained for over nine months at room temperature; and cost-effective formulation using pharmaceutically acceptable carriers,' the statement added. ICMR further said that it intends to licence the technology for AdFalciVax to eligible organisations and manufacturers for further development, manufacture, and commercialisation under non-exclusive agreements. This approach aims to enable wider outreach and maximize public health benefits, and all collaborations will adhere to ICMR's intellectual property policy. ICMR would provide technical support through its team of experienced scientists in study planning, product development, development of study protocol, results or data analysis, outcome assessment, safety and efficacy assessment, product improvement, etc. 'Subsequent to the execution of the agreement such companies/manufacturers shall be responsible to pay the Royalty @ 2% on Net sales, as applicable, according to the ICMR Guidelines for Technology Development Collaboration...,' the statement said. It added that the introduction and rollout of malaria vaccines, such as RTS,S and R21/Matrix-M, have shown promise in reducing disease incidence, particularly among young children in high-burden areas. While significant progress has been made in combating malaria, the global burden remains substantial. In order to address the goal of malaria elimination, an improved vaccine with better efficacy needs to induce protection against infection in human hosts as well as block or reduce transmission to the mosquito vector. 'In this proposed technology, we developed a process for the production of P. falciparum recombinant chimeric malaria antigen (AdFalciVax) … and have tested it for improved immunogenicity with different adjuvant formulations… It has been hypothesized that a combination of Pre-erythrocytic/Anti-Infection Vaccines (AIV) with Transmission-blocking Vaccines (TBV) will reduce the force of infection and be more efficacious than an AIV, like RTS,S or R21/Matrix-M alone,' the statement added.
